Last updated on May 2018

Cognite Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease


Brief description of study

Cognite Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease

Detailed Study Description

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in an early stage AD population.

Clinical Study Identifier: TX143284

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )